HOOKIPA Pharma HOOK 深 滬
已收盤 08-07 16:00:00 美东时间
0.8403
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8403
- 總市值 843.58万
- 52周最高 5.66
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.721
- 委 比 0.00%
- 總股本 1003.90万
- 歷史最高 200.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.721
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hookipa Pharma Sells Oncology Assets to NeoTrail Therapeutics
Hookipa Pharma Sells Oncology Assets to NeoTrail Therapeutics HOOKIPA Pharma Inc. has agreed to sell its immuno-oncology assets, including the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. The purchase price for the assets has not been disclosed. The agreement wa
02-03 21:31
Hookipa Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics
Hookipa Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics HOOKIPA Pharma Inc. has announced the sale of its immuno-oncology assets, including the HB-200 and HB-700 development programs, to NeoTrail Therapeutics, Inc. The transaction was formalized on January 28, 2026, and is expected to c
02-03 21:30
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
HOOKIPA Pharma将针对HPV16阳性癌症和KRAS突变癌症的免疫疗法项目HB-200和HB-700出售给NeoTrail Therapeutics，交易金额未披露。HB-200已获FDA快速通道认证，HB-700即将进入I期试验。交易预计于2026年第二季度完成。
02-03 13:30
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
HOOKIPA Pharma Inc. announced the completion of the sale of its HB-400 and certain HB-500 assets to Gilead Sciences, Inc. The HB-400 program is in clinical development for hepatitis B, while HB-500 targets HIV. The transaction was finalized on October 30, 2025, following an asset purchase agreement signed on May 21, 2025.
2025-10-31 12:00
Hookipa Pharma Approves Asset Sale and Liquidation
An update from Hookipa Pharma ( ($HOOK) ) is now available. On July 29, 2025, H...
2025-07-30 04:44
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
HOOKIPA Pharma Inc. announced its intention to voluntarily delist from the Nasdaq Capital Market and deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934. The company plans to suspend its reporting obligations under Section 15(d) after stockholder approval of the sale of its assets related to the HB-400 and HB-500 programs, which are in clinical development for treating hepatitis B virus and hum...
2025-07-18 20:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Vigil Neuroscience (NASDAQ:VIGL) stock increased by 243.7% to $7.94 du...
2025-05-22 20:10
HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from
2025-05-16 06:28
困境Biotech这就不收购了？
2025.02.25 本文字数：995，阅读时长大约3分钟 导读：HOOKIPA Pharma因研发管线受挫、罗氏终止合作及投资机构信心不足，曾计划收购...
2025-02-25 15:21
HC Wainwright & Co. Downgrades HOOKIPA Pharma to Neutral
HC Wainwright & Co. analyst Arthur He downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Buy to Neutral.
2025-01-10 20:27
